A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
Identifieur interne : 000420 ( PubMed/Corpus ); précédent : 000419; suivant : 000421A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
Auteurs : Eftyhia Vardas ; Pontiano Kaleebu ; Linda-Gail Bekker ; Anwar Hoosen ; Elwyn Chomba ; Philip R. Johnson ; Pervin Anklesaria ; Josephine Birungi ; Burc Barin ; Mark Boaz ; Josephine Cox ; Jennifer Lehrman ; Gwynn Stevens ; Jill Gilmour ; Tony Tarragona ; Peter Hayes ; Sarah Lowenbein ; Eva Kizito ; Patricia Fast ; Alison E. Heald ; Claudia SchmidtSource :
- AIDS research and human retroviruses [ 1931-8405 ] ; 2010.
English descriptors
- KwdEn :
- AIDS Vaccines (administration & dosage), AIDS Vaccines (adverse effects), AIDS Vaccines (immunology), Adult, Antibodies, Neutralizing (blood), Antibody Formation, Dependovirus (immunology), Double-Blind Method, Female, Genetic Vectors (immunology), HIV Antibodies (blood), HIV Infections (immunology), HIV Infections (prevention & control), HIV-1 (immunology), Humans, Immunization Schedule, Male, Middle Aged, T-Lymphocytes (immunology), T-Lymphocytes (virology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (adverse effects), Vaccines, Synthetic (immunology), Young Adult.
- MESH :
- chemical , administration & dosage : AIDS Vaccines, Vaccines, Synthetic.
- chemical , adverse effects : AIDS Vaccines, Vaccines, Synthetic.
- chemical , blood : Antibodies, Neutralizing, HIV Antibodies.
- chemical , immunology : AIDS Vaccines, Vaccines, Synthetic.
- immunology : Dependovirus, Genetic Vectors, HIV Infections, HIV-1, T-Lymphocytes.
- prevention & control : HIV Infections.
- virology : T-Lymphocytes.
- Adult, Antibody Formation, Double-Blind Method, Female, Humans, Immunization Schedule, Male, Middle Aged, Young Adult.
Abstract
The recombinant vaccine, tgAAC09, based on an adeno-associated virus serotype 2 (AAV2) vector encoding HIV-1 subtype C Gag, protease, and part of reverse transcriptase, induced robust T cell and antibody responses in nonhuman primates. In a previous phase I study in 80 healthy HIV-seronegative European and Indian adults, the vaccine was generally safe, well tolerated, and modestly immunogenic when administered once at doses up to 3 x 10(11) DRP. This phase II double-blind, randomized, placebo-controlled trial tested two administrations and a higher dosage of tgAAC009. Ninety-one healthy HIV-seronegative adults from three African countries were given one of three dosage levels of tgAAC09 (3 x 10(10), 3 x 10(11), or 3 x 10(12) DRP) intramuscularly, either at a 6- or 12-month interval; follow-up was 18 months. Overall, 65% and 57% of vaccine recipients experienced local and systemic signs and symptoms, respectively, most being mild. Frequency and severity were not dose related and were similar to those in placebo recipients. No vaccine-related serious adverse events were reported. Overall, HIV-specific T cell responses were detected by IFN-gamma ELISPOT in 17/69 (25%) vaccine recipients with 38% (10/26) responders in the highest dosage group. The response rate improved significantly with boosting at 6, but not 12 months, in the 3 x 10(11) and 3 x 10(12) dosage groups only. Neutralizing antibody titers to the AAV2 did not alter the frequency of immune responses to HIV. Two doses of tgAAC09 were well tolerated at the dosage levels given. Fewer than half the recipients of the highest vaccine dosage, 3 x 10(12) DRP, had T cell responses to HIV.
DOI: 10.1089/aid.2009.0242
PubMed: 20666584
Links to Exploration step
pubmed:20666584Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.</title><author><name sortKey="Vardas, Eftyhia" sort="Vardas, Eftyhia" uniqKey="Vardas E" first="Eftyhia" last="Vardas">Eftyhia Vardas</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Kaleebu, Pontiano" sort="Kaleebu, Pontiano" uniqKey="Kaleebu P" first="Pontiano" last="Kaleebu">Pontiano Kaleebu</name></author><author><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda-Gail" last="Bekker">Linda-Gail Bekker</name></author><author><name sortKey="Hoosen, Anwar" sort="Hoosen, Anwar" uniqKey="Hoosen A" first="Anwar" last="Hoosen">Anwar Hoosen</name></author><author><name sortKey="Chomba, Elwyn" sort="Chomba, Elwyn" uniqKey="Chomba E" first="Elwyn" last="Chomba">Elwyn Chomba</name></author><author><name sortKey="Johnson, Philip R" sort="Johnson, Philip R" uniqKey="Johnson P" first="Philip R" last="Johnson">Philip R. Johnson</name></author><author><name sortKey="Anklesaria, Pervin" sort="Anklesaria, Pervin" uniqKey="Anklesaria P" first="Pervin" last="Anklesaria">Pervin Anklesaria</name></author><author><name sortKey="Birungi, Josephine" sort="Birungi, Josephine" uniqKey="Birungi J" first="Josephine" last="Birungi">Josephine Birungi</name></author><author><name sortKey="Barin, Burc" sort="Barin, Burc" uniqKey="Barin B" first="Burc" last="Barin">Burc Barin</name></author><author><name sortKey="Boaz, Mark" sort="Boaz, Mark" uniqKey="Boaz M" first="Mark" last="Boaz">Mark Boaz</name></author><author><name sortKey="Cox, Josephine" sort="Cox, Josephine" uniqKey="Cox J" first="Josephine" last="Cox">Josephine Cox</name></author><author><name sortKey="Lehrman, Jennifer" sort="Lehrman, Jennifer" uniqKey="Lehrman J" first="Jennifer" last="Lehrman">Jennifer Lehrman</name></author><author><name sortKey="Stevens, Gwynn" sort="Stevens, Gwynn" uniqKey="Stevens G" first="Gwynn" last="Stevens">Gwynn Stevens</name></author><author><name sortKey="Gilmour, Jill" sort="Gilmour, Jill" uniqKey="Gilmour J" first="Jill" last="Gilmour">Jill Gilmour</name></author><author><name sortKey="Tarragona, Tony" sort="Tarragona, Tony" uniqKey="Tarragona T" first="Tony" last="Tarragona">Tony Tarragona</name></author><author><name sortKey="Hayes, Peter" sort="Hayes, Peter" uniqKey="Hayes P" first="Peter" last="Hayes">Peter Hayes</name></author><author><name sortKey="Lowenbein, Sarah" sort="Lowenbein, Sarah" uniqKey="Lowenbein S" first="Sarah" last="Lowenbein">Sarah Lowenbein</name></author><author><name sortKey="Kizito, Eva" sort="Kizito, Eva" uniqKey="Kizito E" first="Eva" last="Kizito">Eva Kizito</name></author><author><name sortKey="Fast, Patricia" sort="Fast, Patricia" uniqKey="Fast P" first="Patricia" last="Fast">Patricia Fast</name></author><author><name sortKey="Heald, Alison E" sort="Heald, Alison E" uniqKey="Heald A" first="Alison E" last="Heald">Alison E. Heald</name></author><author><name sortKey="Schmidt, Claudia" sort="Schmidt, Claudia" uniqKey="Schmidt C" first="Claudia" last="Schmidt">Claudia Schmidt</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20666584</idno><idno type="pmid">20666584</idno><idno type="doi">10.1089/aid.2009.0242</idno><idno type="wicri:Area/PubMed/Corpus">000420</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000420</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.</title><author><name sortKey="Vardas, Eftyhia" sort="Vardas, Eftyhia" uniqKey="Vardas E" first="Eftyhia" last="Vardas">Eftyhia Vardas</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Kaleebu, Pontiano" sort="Kaleebu, Pontiano" uniqKey="Kaleebu P" first="Pontiano" last="Kaleebu">Pontiano Kaleebu</name></author><author><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda-Gail" last="Bekker">Linda-Gail Bekker</name></author><author><name sortKey="Hoosen, Anwar" sort="Hoosen, Anwar" uniqKey="Hoosen A" first="Anwar" last="Hoosen">Anwar Hoosen</name></author><author><name sortKey="Chomba, Elwyn" sort="Chomba, Elwyn" uniqKey="Chomba E" first="Elwyn" last="Chomba">Elwyn Chomba</name></author><author><name sortKey="Johnson, Philip R" sort="Johnson, Philip R" uniqKey="Johnson P" first="Philip R" last="Johnson">Philip R. Johnson</name></author><author><name sortKey="Anklesaria, Pervin" sort="Anklesaria, Pervin" uniqKey="Anklesaria P" first="Pervin" last="Anklesaria">Pervin Anklesaria</name></author><author><name sortKey="Birungi, Josephine" sort="Birungi, Josephine" uniqKey="Birungi J" first="Josephine" last="Birungi">Josephine Birungi</name></author><author><name sortKey="Barin, Burc" sort="Barin, Burc" uniqKey="Barin B" first="Burc" last="Barin">Burc Barin</name></author><author><name sortKey="Boaz, Mark" sort="Boaz, Mark" uniqKey="Boaz M" first="Mark" last="Boaz">Mark Boaz</name></author><author><name sortKey="Cox, Josephine" sort="Cox, Josephine" uniqKey="Cox J" first="Josephine" last="Cox">Josephine Cox</name></author><author><name sortKey="Lehrman, Jennifer" sort="Lehrman, Jennifer" uniqKey="Lehrman J" first="Jennifer" last="Lehrman">Jennifer Lehrman</name></author><author><name sortKey="Stevens, Gwynn" sort="Stevens, Gwynn" uniqKey="Stevens G" first="Gwynn" last="Stevens">Gwynn Stevens</name></author><author><name sortKey="Gilmour, Jill" sort="Gilmour, Jill" uniqKey="Gilmour J" first="Jill" last="Gilmour">Jill Gilmour</name></author><author><name sortKey="Tarragona, Tony" sort="Tarragona, Tony" uniqKey="Tarragona T" first="Tony" last="Tarragona">Tony Tarragona</name></author><author><name sortKey="Hayes, Peter" sort="Hayes, Peter" uniqKey="Hayes P" first="Peter" last="Hayes">Peter Hayes</name></author><author><name sortKey="Lowenbein, Sarah" sort="Lowenbein, Sarah" uniqKey="Lowenbein S" first="Sarah" last="Lowenbein">Sarah Lowenbein</name></author><author><name sortKey="Kizito, Eva" sort="Kizito, Eva" uniqKey="Kizito E" first="Eva" last="Kizito">Eva Kizito</name></author><author><name sortKey="Fast, Patricia" sort="Fast, Patricia" uniqKey="Fast P" first="Patricia" last="Fast">Patricia Fast</name></author><author><name sortKey="Heald, Alison E" sort="Heald, Alison E" uniqKey="Heald A" first="Alison E" last="Heald">Alison E. Heald</name></author><author><name sortKey="Schmidt, Claudia" sort="Schmidt, Claudia" uniqKey="Schmidt C" first="Claudia" last="Schmidt">Claudia Schmidt</name></author></analytic><series><title level="j">AIDS research and human retroviruses</title><idno type="eISSN">1931-8405</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS Vaccines (administration & dosage)</term><term>AIDS Vaccines (adverse effects)</term><term>AIDS Vaccines (immunology)</term><term>Adult</term><term>Antibodies, Neutralizing (blood)</term><term>Antibody Formation</term><term>Dependovirus (immunology)</term><term>Double-Blind Method</term><term>Female</term><term>Genetic Vectors (immunology)</term><term>HIV Antibodies (blood)</term><term>HIV Infections (immunology)</term><term>HIV Infections (prevention & control)</term><term>HIV-1 (immunology)</term><term>Humans</term><term>Immunization Schedule</term><term>Male</term><term>Middle Aged</term><term>T-Lymphocytes (immunology)</term><term>T-Lymphocytes (virology)</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (adverse effects)</term><term>Vaccines, Synthetic (immunology)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>AIDS Vaccines</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>AIDS Vaccines</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>HIV Antibodies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>AIDS Vaccines</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Dependovirus</term><term>Genetic Vectors</term><term>HIV Infections</term><term>HIV-1</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Antibody Formation</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Immunization Schedule</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The recombinant vaccine, tgAAC09, based on an adeno-associated virus serotype 2 (AAV2) vector encoding HIV-1 subtype C Gag, protease, and part of reverse transcriptase, induced robust T cell and antibody responses in nonhuman primates. In a previous phase I study in 80 healthy HIV-seronegative European and Indian adults, the vaccine was generally safe, well tolerated, and modestly immunogenic when administered once at doses up to 3 x 10(11) DRP. This phase II double-blind, randomized, placebo-controlled trial tested two administrations and a higher dosage of tgAAC009. Ninety-one healthy HIV-seronegative adults from three African countries were given one of three dosage levels of tgAAC09 (3 x 10(10), 3 x 10(11), or 3 x 10(12) DRP) intramuscularly, either at a 6- or 12-month interval; follow-up was 18 months. Overall, 65% and 57% of vaccine recipients experienced local and systemic signs and symptoms, respectively, most being mild. Frequency and severity were not dose related and were similar to those in placebo recipients. No vaccine-related serious adverse events were reported. Overall, HIV-specific T cell responses were detected by IFN-gamma ELISPOT in 17/69 (25%) vaccine recipients with 38% (10/26) responders in the highest dosage group. The response rate improved significantly with boosting at 6, but not 12 months, in the 3 x 10(11) and 3 x 10(12) dosage groups only. Neutralizing antibody titers to the AAV2 did not alter the frequency of immune responses to HIV. Two doses of tgAAC09 were well tolerated at the dosage levels given. Fewer than half the recipients of the highest vaccine dosage, 3 x 10(12) DRP, had T cell responses to HIV.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20666584</PMID><DateCreated><Year>2010</Year><Month>08</Month><Day>13</Day></DateCreated><DateCompleted><Year>2010</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1931-8405</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>AIDS research and human retroviruses</Title><ISOAbbreviation>AIDS Res. Hum. Retroviruses</ISOAbbreviation></Journal><ArticleTitle>A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.</ArticleTitle><Pagination><MedlinePgn>933-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/aid.2009.0242</ELocationID><Abstract><AbstractText>The recombinant vaccine, tgAAC09, based on an adeno-associated virus serotype 2 (AAV2) vector encoding HIV-1 subtype C Gag, protease, and part of reverse transcriptase, induced robust T cell and antibody responses in nonhuman primates. In a previous phase I study in 80 healthy HIV-seronegative European and Indian adults, the vaccine was generally safe, well tolerated, and modestly immunogenic when administered once at doses up to 3 x 10(11) DRP. This phase II double-blind, randomized, placebo-controlled trial tested two administrations and a higher dosage of tgAAC009. Ninety-one healthy HIV-seronegative adults from three African countries were given one of three dosage levels of tgAAC09 (3 x 10(10), 3 x 10(11), or 3 x 10(12) DRP) intramuscularly, either at a 6- or 12-month interval; follow-up was 18 months. Overall, 65% and 57% of vaccine recipients experienced local and systemic signs and symptoms, respectively, most being mild. Frequency and severity were not dose related and were similar to those in placebo recipients. No vaccine-related serious adverse events were reported. Overall, HIV-specific T cell responses were detected by IFN-gamma ELISPOT in 17/69 (25%) vaccine recipients with 38% (10/26) responders in the highest dosage group. The response rate improved significantly with boosting at 6, but not 12 months, in the 3 x 10(11) and 3 x 10(12) dosage groups only. Neutralizing antibody titers to the AAV2 did not alter the frequency of immune responses to HIV. Two doses of tgAAC09 were well tolerated at the dosage levels given. Fewer than half the recipients of the highest vaccine dosage, 3 x 10(12) DRP, had T cell responses to HIV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vardas</LastName><ForeName>Eftyhia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaleebu</LastName><ForeName>Pontiano</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bekker</LastName><ForeName>Linda-Gail</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Hoosen</LastName><ForeName>Anwar</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chomba</LastName><ForeName>Elwyn</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Philip R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Anklesaria</LastName><ForeName>Pervin</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Birungi</LastName><ForeName>Josephine</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Barin</LastName><ForeName>Burc</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Boaz</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Josephine</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lehrman</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Gwynn</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gilmour</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tarragona</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lowenbein</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kizito</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fast</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Heald</LastName><ForeName>Alison E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00482027</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MC_U950097145</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AIDS Res Hum Retroviruses</MedlineTA><NlmUniqueID>8709376</NlmUniqueID><ISSNLinking>0889-2229</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016915">AIDS Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015483">HIV Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016915" MajorTopicYN="N">AIDS Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015483" MajorTopicYN="N">HIV Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20666584</ArticleId><ArticleId IdType="doi">10.1089/aid.2009.0242</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20666584
|texte= A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20666584" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |